[ad_1]
The Bacillus calmet-Guerin (BCG) vaccine was originally invented to prevent tuberculosis. But later there was some evidence that the vaccine might protect people from other infections as well.
John Campbell, professor at Exeter School of Medicine in the UK, said: “The BCG vaccine is widely used to boost the body’s immune system. As a result, the vaccine can provide some protection against Covid-19. “
More than 100 million children around the world are vaccinated against tuberculosis (TB) each year. The vaccine can also help adults fight the coronavirus, health experts say.
Professor Campbell said: “We are working to ensure that the BCG vaccine is helpful in protecting people at risk from Covid-19.” If that happened, we could all save lives with this affordable and affordable vaccine. “
According to the BBC, about 1,000 people will take part in the BCG vaccination trial at the University of Exeter in England. The UK has launched the experiment as part of an international initiative.
Tests are also being carried out in Australia, the Netherlands, Spain and Brazil and a total of 10,000 people participate in these tests. The BCG vaccine trial is also being carried out in South Africa to protect against Covid-19.
Volunteers will be taken before winter to a trial in the UK. Officials have warned that coronavirus infections could reach alarming proportions during the winter.
The country is already fighting to prevent a daily record of coronavirus infections. At that time, the BCG vaccine can be helpful for people fighting the disease.
The World Health Organization (WHO) said in an article in the medical journal Tedros Adhanam Gabrieusus Lancet that the BCG vaccine could be used to treat the condition until a specific and effective vaccine for Covid-19 is available.
He hopes the vaccine will be an important tool in the event of a Kovid-19 outbreak and any future epidemics.
However, the BCG vaccine does not provide long-term protection. So those who took the BCG vaccine in childhood will now need to get vaccinated again if they want to benefit from this vaccine.
According to the BBC, previous clinical trials have shown that the BCG vaccine in Guinea-Bissau protects 38 percent of newborns from pneumonia and sepsis.
On the other hand, studies on the BCG vaccine in South Africa found that the vaccine reduced the incidence of nasal, throat and lung infections by 63 percent; The vaccine has also reduced the incidence of the yellow fever virus in the Netherlands.
[ad_2]
